Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1186/S13023-019-1291-2 | ||||
| Año | 2020 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background Limb-girdle muscular dystrophy (LGMD) is a group of neuromuscular disorders of heterogeneous genetic etiology with more than 30 directly related genes. LGMD is characterized by progressive muscle weakness involving the shoulder and pelvic girdles. An important differential diagnosis among patients presenting with proximal muscle weakness (PMW) is late-onset Pompe disease (LOPD), a rare neuromuscular glycogen storage disorder, which often presents with early respiratory insufficiency in addition to PMW. Patients with PMW, with or without respiratory symptoms, were included in this study of Latin American patients to evaluate the profile of variants for the included genes related to LGMD recessive (R) and LOPD and the frequency of variants in each gene among this patient population. Results Over 20 institutions across Latin America (Brazil, Argentina, Peru, Ecuador, Mexico, and Chile) enrolled 2103 individuals during 2016 and 2017. Nine autosomal recessive LGMDs and Pompe disease were investigated in a 10-gene panel (ANO5, CAPN3, DYSF, FKRP, GAA, SGCA, SGCB, SGCD, SGCG, TCAP) based on reported disease frequency in Latin America. Sequencing was performed with Illumina's NextSeq500 and variants were classified according to ACMG guidelines; pathogenic and likely pathogenic were treated as one category (P) and variants of unknown significance (VUS) are described. Genetic variants were identified in 55.8% of patients, with 16% receiving a definitive molecular diagnosis; 39.8% had VUS. Nine patients were identified with Pompe disease. Conclusions The results demonstrate the effectiveness of this targeted genetic panel and the importance of including Pompe disease in the differential diagnosis for patients presenting with PMW.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | BEVILACQUA-RIVAS, JORGE ALFREDO | Hombre |
Universidad de Chile - Chile
CLIN DAVILA - Chile Hospital Clínico de la Universidad de Chile - Chile Clínica Dávila - Chile Hospital Clínico Universidad de Chile - Chile |
| 2 | Guecaimburu Ehuletche, Maria del Rosario | Mujer |
UdelaR - Uruguay
Universidad La República - Uruguay Universidad de la República - Uruguay |
| 3 | Perna, Abayuba | - |
UdelaR - Uruguay
Hospital de Clínicas Dr. Manuel Quíntela - Uruguay Universidad La República - Uruguay Universidad de la República - Uruguay |
| 4 | Dubrovsky, Alberto | Hombre |
Favaloro Fdn - Argentina
Fundacion Favaloro - Argentina |
| 5 | Franca, Marcondes C. | - |
Univ Campinas UNICAMP - Brasil
Universidade Estadual de Campinas - Brasil |
| 6 | Vargas, Steven | Hombre |
Ctr Neurol & Neurosurg - México
Neurology and Neurosurgery National Institute - México |
| 7 | Hegde, Madhuri | Mujer |
PerkinElmer - Estados Unidos
PerkinElmer, Inc. - Estados Unidos |
| 8 | Claeys, Kristl | Mujer |
Univ Hosp Leuven - Bélgica
Katholieke Univ Leuven - Bélgica KU Leuven– University Hospital Leuven - Bélgica KU Leuven - Bélgica |
| 9 | Straub, V. | Hombre |
Newcastle Univ - Reino Unido
Newcastle University, United Kingdom - Reino Unido University of Newcastle upon Tyne, Faculty of Medical Sciences - Reino Unido |
| 10 | Daba, Nadia | Mujer |
Sanofi - Emiratos Árabes Unidos
Sanofi - Países Bajos Sanofi Pasteur - Emiratos Árabes Unidos Sanofi S.A. - Francia |
| 11 | Faria, Roberta | Mujer |
Sanofi - Brasil
Sanofi Pasteur - Brasil Sanofi Pasteur - Emiratos Árabes Unidos |
| 12 | Periquet, Magali | Mujer |
Sanofi - Países Bajos
Sanofi Genzyme - Países Bajos Sanofi - Brasil Sanofi Genzyme - Estados Unidos |
| 13 | Sparks, Susan | Mujer |
Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos Sanofi Genzyme - Países Bajos |
| 14 | Thibault, Nathan | Hombre |
Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos Sanofi Genzyme - Países Bajos |
| 15 | Araujo, Roberto | Hombre |
Sanofi Genzyme - Estados Unidos
Genzyme Corporation - Estados Unidos Sanofi Genzyme - Países Bajos |
| Agradecimiento |
|---|
| This study was funded by Sanofi Genzyme. |
| JAB has received lecture fees from Sanofi-Genzyme; MRGE has nothing to disclose; AP has received funding from Sanofi Genzyme; AD has taken part in advisory boards and given lectures for Sanofi Genzyme; MF has taken part in advisory boards and given lectures for Sanofi Genzyme; SV has received grant/ research support, has served as a consultant, and served on the speakers bureau for Sanofi Genzyme; MH has nothing to disclose; KGC received travel and research grant from Sanofi Genzyme, unrelated to this study; VS has received speaker honoraria from Sanofi Genzyme and funding for a collaborative sequencing project unrelated to this study; ND, RF, MP, SS, NT, and RA are employees of Sanofi Genzyme and Sanofi shareholders. |